CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.

Authors :: Kumar, Shaji
Bachier, Carlos R.
Cavo, Michele
Corradini, Paolo
Delforge, Michel
Janowski, Wojt
Lesokhin, Alexander M.
Mina, Roberto
Paris, Laura
Rosiñol, Laura
Quach, Hang
Goodman, Grant R.
Nakamura, Rin
Samineni, Divya
Shah, Vallari
Wassner Fritsch, Elisabeth
Berdeja, Jesus G.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS8064-TPS8064, 1p
Publication Year :: 2023

Full Text Access

Tools